More recently, novel targeted cancer therapies, including vascular endothelial growth factor (VEGF) inhibitors, proteasome inhibitors (PI), and tyrosine kinase inhibitors (TKI), have been recognized as significant triggers of hypertension (Table 2) [9]. Here, VEGFA is linked to cancer.